UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 31 2007
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
DISPOSAL
NOVO NORDISK'S DIVESTMENT OF ITS OWNERSHIP OF DAKO'S BUSINESS ACTIVITIES HAS NOW
BEEN COMPLETED
As communicated in Stock Exchange Announcement no 6 on 28 February 2007, the
Board of Directors of Dako A/S decided to divest its only subsidiary Dako
Denmark A/S to the private equity fund EQT V. Dako Denmark A/S was the sole
owner of the global business activities for the Dako Group, one of the world's
leading companies within cancer diagnostics. As previously communicated, Novo
Nordisk owns 27% of Dako A/S.
The sales agreement was subject to a number of conditions. All conditions have
now been fulfilled including the approval of the transaction by the relevant
competition authorities and thus the divestment was completed today.
As a consequence of this transaction, and as previously communicated, Novo
Nordisk expects to record a tax-exempt income of around DKK 1.5 billion in
relation to Dako's sale of Dako Denmark A/S, of which around DKK 1.4 billion is
now expected to be recorded in the second quarter of 2007. The remaining around
DKK 100 million is subject to the outcome of certain warranty obligations and is
expected to be recorded in the first half of 2008. The income from the
transaction will be recorded under 'Share of profit in associated companies' in
the 'net financials' part of the income statement.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The
company has the broadest diabetes product portfolio in the industry, including
the most advanced products within the area of insulin delivery systems. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79
countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.
The Dako Group is a Denmark-based, world leading provider of systems for cancer
diagnostics. Hospital and research laboratories worldwide use Dako products to
make precise diagnoses and determine the most effective treatment of patients
suffering from cancer. With more than 1,300 employees and a presence in more
than 20 countries, Dako covers most of the global pathology markets. Remaining
markets are covered by distributors in 50 countries. www.dako.com
CONTACTS FOR FURTHER INFORMATION:
Media: Investors:
Outside North America: Outside North America:
Michael Laub Mads Veggerby Lausten
Tel: (+45) 4442 1960 Tel: (+45) 44437919
E-mail: mclb@novonordisk.com E-mail: mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
E-mail: hrmm@novonordisk.com
In North America: In North America:
Lori Moore Christian Qvist Frandsen
Tel: (+1) 609 919 7991 Tel: (+1) 609 919 7937
E-mail: lrmo@novonordisk.com E-mail: cqfr@novonordisk.com
Stock Exchange Announcement No 14 / 2007
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: May 31 2007 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer